Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography

被引:24
作者
Granda, BW
Giancarlo, GM
von Moltke, LL
Greenblatt, DJ
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
[2] Tufts Univ, New England Med Ctr Hosp, Div Clin Pharmacol, Boston, MA 02111 USA
关键词
ritonavir; protease inhibitors; drug interactions;
D O I
10.1016/S1056-8719(99)00013-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A method has been developed to quantify ritonavir concentrations in human plasma and in mouse serum, liver, and brain using high-performance liquid chromatography. Extraction recoveries for ritonavir and its internal standard averaged greater than 95%. Within-day variability, expressed as a coefficient of variation, averaged 6% over the concentration range 0.5 mu g/mL to 15 mu g/mL ritonavir, and between-day variability averaged 5.6% over 5 mu g/mL to 15 mu g/mL ritonavir. The method was applied to quantitation of ritonavir in mouse serum and tissue. Measured values deviated less than 5% from the actual values in mouse serum, liver, and brain samples containing 5 mu g/mL ritonavir. The slopes of calibration curves for extracted calf serum, mouse serum, mouse liver and mouse brain standards were nearly identical to the calibration slope of standards which were not extracted. All curves were linear through zero, and r(2) was no less than 0.998 for any form of calibration. In addition, there was no chromatographic interference from commonly prescribed medications. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:235 / 239
页数:5
相关论文
共 16 条
[1]  
BERTZ RJ, 1996, INT C AIDS, V11, P89
[2]   The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin [J].
Cato, A ;
Cavanaugh, J ;
Shi, H ;
Hsu, A ;
Leonard, J ;
Granneman, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (04) :414-421
[3]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[4]   A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE [J].
DANNER, SA ;
CARR, A ;
LEONARD, JM ;
LEHMAN, LM ;
GUDIOL, F ;
GONZALES, J ;
RAVENTOS, A ;
RUBIO, R ;
BOUZA, E ;
PINTADO, V ;
AGUADO, AG ;
DELOMAS, JG ;
DELGADO, R ;
BORLEFFS, JCC ;
HSU, A ;
VALDES, JM ;
BOUCHER, CAB ;
COOPER, DA ;
GIMENO, C ;
CLOTET, B ;
TOR, J ;
FERRER, E ;
MARTINEZ, PL ;
MORENO, S ;
ZANCADA, G ;
ALCAMI, J ;
NORIEGA, AR ;
PULIDO, F ;
GLASSMAN, HN .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1528-1533
[5]  
Denissen JF, 1997, DRUG METAB DISPOS, V25, P489
[6]   Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir [J].
Eagling, VA ;
Back, DJ ;
Barry, MG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (02) :190-194
[7]   Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects [J].
Hsu, A ;
Granneman, GR ;
Witt, G ;
Locke, C ;
Denissen, J ;
Molla, A ;
Valdes, J ;
Smith, J ;
Erdman, K ;
Lyons, N ;
Niu, P ;
Decourt, JP ;
Fourtillan, JB ;
Girault, J ;
Leonard, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :898-905
[8]   The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors [J].
Kim, RB ;
Fromm, MF ;
Wandel, C ;
Leake, B ;
Wood, AJJ ;
Roden, DM ;
Wilkinson, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :289-294
[9]   Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography [J].
Marsh, KC ;
Eiden, E ;
McDonald, E .
JOURNAL OF CHROMATOGRAPHY B, 1997, 704 (1-2) :307-313
[10]  
Merry C, 1998, AIDS, V12, P325